健脾清热活血方调控PGRP-3、PGRP-4、IL-22防治溃疡性结肠炎研究

李锦颜; 陈玉; 张涛; 李华燕; 王小平

doi:10.3969/j.issn.1671-038X.2016.07.02

健脾清热活血方调控PGRP-3、PGRP-4、IL-22防治溃疡性结肠炎研究

- 1 广西中医药大学附属瑞康医院消化内科, 广西南宁 530011;
- 2 广西梧州市人民医院中医科, 广西梧州 543000;
- 3 江门市第二人民医院内科, 广东江门 529200;
- 4 江西中医药高等专科学校, 江西抚州 344700
基金项目:
广西自然科学基金(No:2013GNSFAA019116)

详细信息

作者简介:
李锦颜,女,在读硕士研究生,主治医师,主要从事中西医结合防治消化系疾病研究

通讯作者: 张涛,E-mail:327664246@qq.com

中图分类号: R574.62

收稿日期: 2015-11-09

Jianpi Qingre Huoxue decoction treating ulcerative colitis by PGRP-3 and PGRP-4 and IL-22

- 1 Department of Gastroenterology, Ruikang Hospital Affiliated to Guangxi University of TCM, Nanning 530011, China;
- 2 Department of Traditional Chinese Medicine, The People's Hospital of Wuzhou, Guangxi 543000, China;
- 3 Department of Internal Medicine, The Second Hospital of Jiangmen City, Jiangmen 529200, China;
- 4 Jiangxi Institute of Chinese Medicine, Fuzhou 344700, China

More Information

Corresponding author: ZHANG Tao, E-mail: 327664246@qq.com

Received Date: 09 November 2015

摘要

摘要: [目的]基于检测溃疡性结肠炎肽聚糖结合蛋白3(PGRP-3)、肽聚糖结合蛋白4(PGRP-4)、IL-22表达及结肠黏膜组织病理学变化,探讨健脾清热活血方干预溃疡性结肠炎的可能机制。[方法]100只Balb-c小鼠按体重随机分为5组即正常组、模型组、低剂量组、中剂量组及高剂量组,每组20只,采用自由引用3%DSS法制备溃疡性结肠炎模型,自第3周起分组给药,模型组予等剂量生理盐水、治疗组分别予不同剂量健脾清热活血方灌胃,连续1周。末次给药后处死全部小鼠,采用苏木精-伊红染色法检测小鼠结肠组织病理学变化,采用Western-blot技术检测结肠黏膜PGRP-3及PGRP-4表达,应用ELISA检测IL-22表达。[结果]光镜下见模型组结肠黏膜充血、肿胀,黏膜固有层及黏膜下层大量炎性细胞浸润,见溃疡形成;而治疗组肠壁黏膜及黏膜下层轻度充血水肿,少量炎细胞浸润,未见明显溃疡。模型组PGRP-3、PGRP-4表达下降;治疗组PGRP-3、PGRP-4表达上升,经比较,差异有统计学意义(P＜0.05)。模型组IL-22表达量为(398.67±68.76)pg/ml,治疗组中低剂量组IL-22表达量为(257.82 ±56.41)pg/ml、中剂量组为(249.32±61.75)pg/ml、高剂量组为(263.69±57.89)pg/ml,治疗组与模型组比较有统计学意义(P＜0.05)。[结论]健脾清热活血方可能通过调控PGRP识别PGN,杀伤外源微生物,传递炎症信号,促进IL-22分泌增加,增强上皮先天防御机制和屏障的完整性,隔离免疫系统与肠道共生菌群之间的直接相互作用,保护肠道免受炎症损伤,从而发挥缓解UC的效用。
- 肽聚糖结合蛋白3 /
- 肽聚糖结合蛋白4 /
- 白介素-22 /
- 溃疡性结肠炎 /
- 健脾清热活血方
Abstract: [Objective] To explore the mechanism of Jianpi Qingre Huoxue decoction(JQHD)in the treatment of ulcerative colitis by observing the expression of PGRP-3,PGRP-4 and IL-22.[Methods] 100 Balb-c mice were randomly divided into normal group,model group,low dosage group,middle dosage group and high dosage group,20 mice in each group.The ulcerative colitis models were made by drinking 3% DSS for 2 weeks.Since the 3 th week,the model group was given equal dose of saline gavage.The latter three groups were treated with different dosage of JQHD gavage for one week.All rats were sacrificed after the last administration.The pathological changes of colonic mucosa were detected by HE staining.The expression of PGRP-3 and PGRP-4 in colonic mucosa was detected by Western-blot and IL-22 with ELISA respectively.[Results] The model group showed colonic mucosa hyperemia swelling,a large number of inflammatory cell infiltration and ulcers in mucosa lamina propria and submucosa under the light microscope.While the intervention groups showed improved inflammatory cell infiltration with no noticeable ulcer and low-grade hyperemia swelling.In the model group,the expression of PGRP-3 and PGRP-4 decreased.The expression of PGRP-3 and PGRP-4 in the JQHD groups increased,with significant difference as compared with the model group(P＜0.05).The expression of IL-22 was 398.67±68.76 pg/ml,257.82 ±56.41 pg/ml,249.32±61.75 pg/ml and 263.69±57.89 pg/ml in the model group,low dosage,middle dosage,high dosage JQHD group respectively.Compared with the model group,JQHD groups showed significant difference(P＜0.05).[Conclusion] JQHD decoction may exert a distinct effect on improving ulcerative colitis by regulating PGRP sensed PGN,eliminating the exogenous microorganisms,mediating the inflammatory signals,resulting in the promotion of IL-22 secretion,enhancement of the integrity of the epithelium and the protection of the immune system and the direct interaction between the immune system and intestinal symbiotic bacteria,so as to protect the intestine from inflammatory injury.
- peptidoglycan recognition Protein 3 /
- peptidoglycan recognition protein 4 /
- intelukin-22 /
- ulcerative colitis /
- Jianpi Qingre Huoxue decoction(JQHD)

HTML全文

参考文献(18)

[1]	DANESE S.New therapies for inflammatory bowel disease:from the bench to the bedside[J].Gut, 2012, 61:918-932.
[2]	ULLMAN TA, ITZKOWITZ SH.Intestinal inflammation and cancer[J].Gastroenterology, 2011, 140:1807-1816.
[3]	LEES CW, BARRETT JC, PARKES M, et al.New IBD genetics:common pathways with other diseases[J].Gut, 2011, 60:1739-1753.
[4]	JING X, ZULFIQAR F, PARK SY, et al.Peptidoglycan recognition protein 3 and Nod2 synergistically protect mice from dextran sodium sulfate-induced colitis[J].J Immunol, 2014, 193:3055-3069.
[5]	ZULFIQAR F, HOZO I, RANGARAJAN S, et al.Genetic association of peptidoglycan recognition protein variants with inflammatory bowel disease[J].PLoS One, 2013, 8:e67393.
[6]	ALBERT EJ, DUPLISEA J, DAWICKI W, et al.Tissue eosinophilia in a mouse model of colitis is highly dependent on TLR2 and independent of mast cells[J].Am J Pathol, 2011, 178:150-160.
[7]	张保静, 陈远能, 黄斌, 等.健脾清热活血方介导Wnt/β-catenin通路对人结肠癌SW480细胞的影响[J].世界华人消化杂志, 2013, 21(9):745-754.
[8]	张保静, 陈远能, 黄斌, 等.健脾清热活血方介导β-catenin、TCF-4表达防治溃疡性结肠炎相关癌变的研究.[J].中国实验方剂学杂志, 2013, 19(20):144-149.
[9]	王喜周, 张涛, 陈远能, 等.健脾清热活血类方药介导β-catenin、C-myc表达干预溃疡性结肠炎相关癌变研究[J].中成药, 2012, 34(2):226-230.
[10]	TANG R, YANG G, ZHANG S, et al.Opposite effects of interferon regulatory factor 1 and osteopontin on the apoptosis of epithelial cells induced by TNF-α in inflammatory bowel disease[J].Inflamm Bowel Dis, 2014, 20:1950-1961.
[11]	NANAU RM, NEUMAN MG.Metabolome and inflammasome in inflammatory bowel disease[J].Transl Res, 2012, 160:1-28.
[12]	KIM HS, SHIN TH, LEE BC, et al.Human umbilical cord blood mesenchymal stem cells reduce colitis in mice by activating NOD2 signaling to COX2[J].Gastroenterology, 2013, 145:1392-403.e1-8.
[13]	SAHA S, JING X, PARK SY, et al.Peptidoglycan recognition proteins protect mice from experimental colitis by promoting normal gut flora and preventing induction of interferon-gamma[J].Cell Host Microbe, 2010, 8:147-162.
[14]	LEE J, GEDDES K, STREUTKER C, et al.Role of mouse peptidoglycan recognition protein PGLYRP2 in the innate immune response to Salmonella enterica serovar Typhimurium infection in vivo[J].Infect Immun, 2012, 80:2645-2654.
[15]	RICHARDSON WM, SODHI CP, RUSSO A, et al.Nucleotide-binding oligomerization domain-2 inhibits toll-like receptor-4 signaling in the intestinal epithelium[J].Gastroenterology, 2010, 139:904-917.e1-6.
[16]	XU AT, LI Y, ZHAO D, et al.High suppressor of cytokine signaling-3 expression impairs STAT3-dependent protective effects of interleukin-22 in ulcerative colitis in remission[J].Inflamm Bowel Dis, 2015, 21:241-250.
[17]	CHI HG, ZHENG XB, WU ZG, et al.Association of the interleukin-22 genetic polymorphisms with ulcerative colitis[J].Diagn Pathol, 2014, 9:183-183.
[18]	LONGMAN RS, DIEHL GE, VICTORIO DA, et al.CXCR1 mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22[J].J Exp Med, 2014, 211:1571-1583.